From FDA labels and ClinicalTrials.gov

Do GLP-1s lower the risk of heart attack and stroke?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

FDA has approved Wegovy, Rybelsus/Ozempic tablets, Trulicity, Victoza, Mounjaro and Ozempic for this, in the words of each label below. 11 outcome trials, by sex (GLP-1s): Major heart events fell 14% in men and 18% in women, with no significant difference between the sexes. People with type 2 diabetes and related conditions. Diabetes Obes Metab, 2025 (pubmed.ncbi.nlm.nih.gov/40932012). ClinicalTrials.gov lists 97 trials of these medicines on it: 13 with posted results and 18 recruiting now.

Read from the registry and PubMed every day. The newest update here is Nov 16, 2026.

FDA approved

What each label says on heart disease

The approved use, word for word from each current label.

  • Wegovy: to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
  • Rybelsus/Ozempic tablets: to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
  • Trulicity: To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
  • Victoza: to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
  • Mounjaro: to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
  • Ozempic: to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
Published results

What the largest trials on heart disease found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

11 outcome trials, by sex

GLP-1s · 85,273 people · Better than the comparison · Meta-analysis

Major heart events fell 14% in men and 18% in women, with no significant difference between the sexes. People with type 2 diabetes and related conditions.

Diabetes Obes Metab, 2025 (pubmed.ncbi.nlm.nih.gov/40932012)

SELECT

Semaglutide · 17,604 people · Better than the comparison · Placebo-controlled randomized trial

In people with heart disease and overweight or obesity, without diabetes, heart death, heart attack or stroke happened in 6.5% on semaglutide 2.4 mg against 8.0% on placebo (hazard ratio 0.80).

N Engl J Med, 2023 (pubmed.ncbi.nlm.nih.gov/37952131)

SURPASS-CVOT

Tirzepatide vs dulaglutide · 13,299 people · Mixed · Head-to-head randomized trial

In type 2 diabetes with heart disease, heart death, heart attack or stroke happened in 12.2% on tirzepatide against 13.1% on dulaglutide. That met the test for no worse (noninferior), not the test for better (P = 0.09).

N Engl J Med, 2025 (pubmed.ncbi.nlm.nih.gov/41406444)

The registry

Trials on heart disease, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Semaglutide42312
Liraglutide2170
Exenatide1810
Tirzepatide712
Orforglipron302
Dulaglutide211
Retatrutide200
MariTide100
Mazdutide101
Posted results

What trials on heart disease reported

Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.

TrialMedicinePhasePeopleResult
SELECTSemaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesitySemaglutidePhase 317,604Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (Participants), From randomisation (week 0) up to 240 weeks. Semaglutide: 569; Placebo: 701.
REWINDResearching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)DulaglutidePhase 39,901Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (Participants), From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years). Placebo: 663; Dulaglutide: 594.
SURPASS-4A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular RiskTirzepatidePhase 32,002Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) (Percentage of HbA1c), Baseline, Week 52. 10 mg Tirzepatide: -2.43; 15 mg Tirzepatide: -2.58; Insulin Glargine: -1.44.
STRIDEA Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 DiabetesSemaglutidePhase 3792Change in Maximum Walking Distance on a Constant Load Treadmill Test (Ratio of maximum walking distance), Baseline (week 0), end of treatment (week 52). Semaglutide: 1.21; Placebo: 1.08.
NCT03038620Impact of Liraglutide 3.0 on Body Fat DistributionLiraglutidePhase 4235Relative Percent Reduction in Visceral Adipose Tissue Mass Measured by MRI (percentage of reduction in VAT), Baseline, 40 weeks. Liraglutide 3.0 mg: 12.49; Placebo: 1.63.
LIPTLIPT - Liraglutide in Polycystic Ovary SyndromeLiraglutidePhase 472Change in Endogenous Thrombin Potential (ETP) (nMolar x minutes), at time 0 and 26 weeks. Liraglutide: -56.7; Placebo: -8.2.
NCT03151005The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOSLiraglutidePhase 470Assessment of Reproductive Functions (mIU/ml), 12 weeks. Metformin-GLP-1 Receptor Agonist: 5.52; Metformin-Oral Contraceptive(OC): 5.33.
STARDUSTLiraglutide and Peripheral Artery DiseaseLiraglutidePhase 460Peripheral Transcutaneous Oxygen Pressure (mmHg), 6 months. Liraglutide Group: 54.2; Control Group: 43.4.
NCT00736229Intravenous Exenatide in Coronary Intensive Care Unit (ICU) PatientsExenatidePhase 440Median Glucose Values From Steady State Through 48 Hours or Until Discharge. (mg/dL), 1-48 hours. Exenatide: 132; Moderate: 127; Intensive: 105.
NCT03260881Liraglutide Effects on Epicardial Fat Inflammatory GenesLiraglutidePhase 438On ClinicalTrials.gov (clinicaltrials.gov)
NCT04216589Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)SemaglutidePhase 251On ClinicalTrials.gov (clinicaltrials.gov)
ON TARGET DMComparison of Type 2 Diabetes Pharmacotherapy RegimensLiraglutideNot phased241,981Incidence of 3-point Major Adverse Cardiovascular Events (MACE) (Participants), 2.5 years. SU Initiators: 11,348; DPP4 Initiators: 393; SGLT2i Initiators: 424; GLP-1RA Initiators: 296.
NCT03010683Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes MellitusLiraglutideNot phased60Differences in Pulse Wave Velocity at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R. (m/s), Baseline, 3 months, 6 months and 12 months, Baseline. Liraglutide: 11.8; Metformin: 11.2.
Recruiting now

Trials on heart disease taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) (clinicaltrials.gov/study/NCT07241390)OrforglipronPhase 3Aug 2031
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes (clinicaltrials.gov/study/NCT06082063)SemaglutidePhase 3Jul 1, 2029
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (clinicaltrials.gov/study/NCT07223593)OrforglipronPhase 3Jun 2028
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial (clinicaltrials.gov/study/NCT07734792)TirzepatidePhase 2/3Jul 31, 2028
Epicardial Cardiac Fat-CT (EPIC-CT) (clinicaltrials.gov/study/NCT07297589)SemaglutidePhase 3Mar 2027
Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis (clinicaltrials.gov/study/NCT07282041)DulaglutidePhase 2/3Dec 1, 2030
Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 Diabetes (clinicaltrials.gov/study/NCT05700877)SemaglutidePhase 4Mar 1, 2029
A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China (clinicaltrials.gov/study/NCT07900438)SemaglutidePhase 4Jan 24, 2030
Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes (clinicaltrials.gov/study/NCT07254572)SemaglutidePhase 4Aug 1, 2029
The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease (clinicaltrials.gov/study/NCT06606821)TirzepatidePhase 4Aug 1, 2028
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity (clinicaltrials.gov/study/NCT07657676)MazdutidePhase 4Dec 31, 2027
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes (clinicaltrials.gov/study/NCT05780905)SemaglutidePhase 4Dec 31, 2026
Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke (clinicaltrials.gov/study/NCT05630586)SemaglutidePhase 2Dec 2027
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV (clinicaltrials.gov/study/NCT07221214)SemaglutidePhase 2Jan 31, 2030
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study (clinicaltrials.gov/study/NCT07588984)SemaglutideNot phasedMay 2029

The 15 largest of 18 recruiting.

From PubMed

Newest papers on GLP-1s and heart disease

  • First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/43013292)

    Randomized trial · JAMA Cardiol · Nov 11, 2026 · Marx N et al.

  • Exploring time-varying cardiovascular effects of GLP-1 receptor agonists: A multi-state network meta-analysis of cardiovascular outcome trials (pubmed.ncbi.nlm.nih.gov/42994759)

    Meta-analysis · Diabetes Res Clin Pract · Nov 6, 2026 · Wang Z et al.

  • Semaglutide and Cardiovascular Death: a Systematic Review and Meta-Analysis Cardioprotective Efficacy of Semaglutide (pubmed.ncbi.nlm.nih.gov/42969445)

    Meta-analysis · Crit Pathw Cardiol · Nov 2, 2026 · Marino G et al.

  • GLP-1-based therapies for reduction of heart failure and cardiovascular outcomes: A systematic review and meta-analysis of randomized controlled trials (pubmed.ncbi.nlm.nih.gov/43024260)

    Meta-analysis · Medicine (Baltimore) · Nov 1, 2026 · Sajid EU et al.

  • Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review (pubmed.ncbi.nlm.nih.gov/42033237)

    Systematic review · Am J Health Syst Pharm · Nov 1, 2026 · Bihelek N et al.

  • Cardiovascular Effects of GLP-1 Receptor Agonists Across Age Groups: An Updated Meta-Analysis of Randomized Controlled Trials (pubmed.ncbi.nlm.nih.gov/42946897)

    Meta-analysis · Diabetes Obes Metab · Oct 27, 2026 · Fujii A et al.

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Updated automatically

What changed in trials on heart disease

  • TrialSemaglutide study now recruiting (was not yet recruiting): GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study (clinicaltrials.gov/study/NCT07588984)
  • TrialTirzepatide study now recruiting (was not yet recruiting): Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial (clinicaltrials.gov/study/NCT07734792)
  • TrialNew Semaglutide study registered: A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China (clinicaltrials.gov/study/NCT07900438)
  • TrialSemaglutide study now active, not recruiting (was not yet recruiting): A Retrospective Real-World Cohort Study (clinicaltrials.gov/study/NCT07781371)

Written from each source's own record as it changes. Every change on GLPcompare

Questions

GLP-1s and heart disease: common questions

What did the largest trial on heart disease find?

11 outcome trials, by sex (GLP-1s, 85,273 people): Major heart events fell 14% in men and 18% in women, with no significant difference between the sexes. People with type 2 diabetes and related conditions.

Is any GLP-1 FDA approved for heart disease?

Yes: Wegovy, Rybelsus/Ozempic tablets, Trulicity, Victoza, Mounjaro and Ozempic. Wegovy's label: to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.

Does insurance cover a GLP-1 for heart disease?

Plans decide, and they usually tie coverage to a medicine's approved uses, so Wegovy, Rybelsus/Ozempic tablets, Trulicity, Victoza, Mounjaro and Ozempic are the place to start. Ask your plan whether it covers the medicine for this diagnosis and whether it needs prior authorization.

Which GLP-1 has been studied most for heart disease?

Semaglutide, with 42 registered trials on it, then Liraglutide with 21. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for heart disease?

18 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.